EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 07.11.2024
Semperit increases profitability in Q1–3 and confirms outlook for 2024
EBITDA plus 12% to EUR 63.9 million, earnings after tax increase to EUR 7.1 million
Free cash flow improves to EUR 22.4 million
EBITDA guidance of around EUR 80 million confirmed for 2024
Vienna, November 7, 2024 – In the first three quarters of 2024, the Semperit Gro...
Semperit: Manfred Stanek appointed new CEO
Vienna, 26 September 2024 – The Supervisory Board of Semperit AG Holding appointed Manfred Stanek as the new CEO of Semperit AG Holding today. He will join the Executive Board on 1March 2025 and take over the role of CEO on 1 April 2025; his mandate as a member of the Executive Board will run until 29 Fe...
Semperit: Manfred Stanek appointed new CEO
Vienna, 26 September 2024 – The Supervisory Board of Semperit AG Holding appointed Manfred Stanek as the new CEO of Semperit AG Holding today. He will join the Executive Board on 1 March 2025 and take over the role of CEO on 1 April 2025; his mandate as a member of the Executive Board will run until 29 F...
Semperit increases profitability in the first half of 2024
EBITDA up 8% to EUR 47.3 million, earnings after tax more than doubled
Free cash flow significantly improved to EUR 23.6 million
Cost-cutting program takes effect: cost reductions of EUR 14.4 million, of which EUR 8.6 million in H1
EBITDA guidance confirmed at around EUR 80 million f...
Semperit finalizes sale of the remaining medical business
Vienna, July 1, 2024 – Semperit has completed the sale of the medical business and transferred the remaining production and packaging of surgical gloves to the buyer of the entire medical business, the Southeast Asian Harps Global, as agreed. Combined under the discontinued operations “Surg...
Semperit: Executive Board Chairman Karl Haider will not extend his contract
Vienna, June 10, 2024 – Karl Haider today informed the Chairman of the Supervisory Board of Semperit AG Holding that he will not be available for an extension of his Executive Board mandate, which expires on March 31, 2025. Karl Haider, who was appointed to the Executive B...
Semperit: Executive Board Chairman Karl Haider will not extend his contract
Vienna, June 10, 2024 – Karl Haider today informed the Chairman of the Supervisory Board of
Semperit AG Holding that he will not be available for an extension of his Executive Board mandate, which expires on March 31, 2025, and that he intends to focus more on non-executiv...
Semperit with stable revenue and 9% EBITDA increase in Q1 2024
Continued operations with revenue of EUR 176.0 million (–0.2%) and EBITDA of EUR 23.0 million (+9.4%)
Cost reductions initiated in the previous year already reduced expenses by EUR 9.9 million, of which EUR 4.1 million was attributable to Q1 2024
EBITDA guidance of around EUR 80 ...
Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business
Continued operations with revenue of EUR 721.1 million (–7.5%), EBITDA of EUR 71.8 million (–28.5%) and positive earnings after tax of EUR 24.9 million (–35.2%)
Cost reductions with a run rate of more than EUR 10 million p...
Semperit Executive Board proposes dividend of EUR 0.5 per share for 2023
Vienna, 5 March 2024 – The Executive Board of Semperit AG Holding has decided today to propose to the Annual General Meeting a dividend of EUR 0.5 per share for the financial year 2023.
The Annual General Meeting of Semperit AG Holding will take place on 23 April 2024.
...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .